Danish healthcare spending cuts

Home/Policies & Legislation | Posted 18/06/2010 post-comment0 Post your comment

In a bid to cut public spending, the Danish government is the latest to announce an austerity package aimed at creating savings of at least DKK 24 billion. The austerity package, as well as slashing unemployment benefits and cutting governmental salaries, also focuses on cost-containment within the healthcare sector.


The government’s austerity package comes as a result of the European Commission’s request that Denmark lowers its public deficit to below 3% of its gross domestic product. The government’s cost-cutting plans, however, are not as harsh as those introduced, for example, in Italy and Spain.

With the Danish government accounting for nearly 85% of total healthcare spending, it is not surprising that the healthcare sector has been identified as an area where cost-savings can be made.

A price freeze on medicine prices has been enforced in Denmark since 2009, ensuring that a drug’s pharmacy purchasing price cannot exceed May 2009 levels. On top of this, in January 2010, a 5% price cut on medicines came into force. This is expected to save DKK 200 million in 2010 and around DKK 700 million by the end of 2012.

These controls will also apply to drugs newly launched in 2010, bringing Danish drug prices in line with the average price recorded in a reference price basket of countries including Austria, Belgium, Finland, Ireland, Norway, Sweden, The Netherlands, Turkey, and the UK. In the past it has been shown that the Danish pharmaceutical market was rather liberal, resulting in Danish hospitals paying as much as 22% more than their Norwegian counterparts for medicines.

The price controls on medicines enforced by the Danish government is not expected to hurt the generics industry in Denmark too much, especially compared to measures specifically targeted at generics introduced in other countries.

comment icon Comments (0)
Post your comment
Related content
PDUFA VI: FDA could promote generics competition
47 MD001813
Home/Policies & Legislation Posted 29/07/2022
House bill passes FDA funding fees but conflicts with Senate bill
User Fee V13H23
Home/Policies & Legislation Posted 15/07/2022
US Senate clarifies status of interchangeable biosimilar exclusivity
Interchangeability V18K30
Home/Policies & Legislation Posted 27/05/2022
Nomenclature of biologicals and biosimilars in Peru
02 AA010638
Home/Policies & Legislation Posted 20/05/2022
Most viewed articles
About GaBI
Home/About GaBI Posted 06/08/2009
EU guidelines for biosimilars
EMA logo 1 V13C15
Home/Guidelines Posted 08/10/2010